Overview
Ambry Genetics, a Tempus Company, specializes in clinical genetic testing using advanced genomic technologies like DNA/RNA analysis and next-generation sequencing (NGS) for hereditary cancers, oncology, neurology, and rare diseases. They offer pharma services supporting drug development across therapeutic areas including gene therapy and cardiovascular diseases, with a CLIA/CAP-certified SuperLab for high-volume and customized testing. Their expertise translates research into actionable insights for pharmaceutical partners and clinicians.
Frequently asked questions
- What pharma services does Ambry Genetics provide?
- Ambry supports drug development with genetic insights for oncology, neurology, cardiovascular diseases, gene therapy, gastroenterology, and rare diseases, using a CLIA/CAP-certified lab for customized research projects.
- What are Ambry's lab certifications and capabilities?
- Their 65,000 sq. ft. SuperLab is CLIA/CAP-certified, New York approved, and equipped for NGS, Sanger sequencing, biomarker development, and high-volume automated testing to ensure precision and efficiency.
- What therapeutic areas does Ambry cover?
- Key areas include oncology (e.g., pan-cancer panels like CancerNext-Expanded), neurology, cardiovascular diseases, gene therapy, gastroenterology, and rare diseases, with comprehensive hereditary cancer testing.